Cytis AG Arranges Distribution Agreement for BioAlliance’s Loramyc® Drug
BASEL, Switzerland, October 29, 2012 /PRNewswire/ –
Swiss based Citys AG has arranged a distribution agreement for the Republic of Iran
for BioAlliance Pharma SA, a company dedicated to the development of orphan oncology drugs
and supportive care products headquartered in Paris. The agreement covers BioAlliance’s
Loramyc(R) drug, a miconazole Lauriad(TM) mucoadhesive buccal tablet for the treatment of
oropharyngeal candidiasis in immunocompromised patients.
“For BioAlliance the agreement concluded through Cytis AG marks the expansion of
Loramyc(R)’s commercialization worldwide, and especially to emergent markets,” declares
Judith Greciet, CEO of BioAlliance Pharma.
Distributor in Iran will be Shafayab Gostar, a company established in 2001. The
agreement will bring an innovative product to Iran that meets a medical need in a market
where some 180,000 new cancer cases are diagnosed every year. Loramyc(R) provides a new
therapeutic solution to patients suffering from oropharyngeal candidiasis, improves their
care, particularly for patients at risk, and their quality of life.
About Cytis AG
Cytis AG (http://www.cytis.ch) is dedicated to the commercialization and promotion in
the fields of biopharmaceuticals, pharmaceuticals, medical equipments and diagnostics via
partnerships, distribution setups or licensing, especially in emerging markets and more
specifically in Middle East and Central Europe. This activity contributes to fulfill unmet
medical needs of patients and develop geographical expansion of innovative companies.
About BioAlliance Pharma SA
Dedicated to cancer and supportive care treatment with a focus on resistance targeting
and orphan products, BioAlliance conceives and develops innovative products, for specialty
markets especially in the hospital setting and for orphan or rare diseases. Created in
1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is
to become a leading player in these fields by coupling innovation to patient needs. The
company’s teams have the key competencies required to identify, develop and register drugs
in Europe and the USA.
Further Information : Patrick Durand Cytis AG Gewerbestrasse 14 4123 Allschwil, Switzerland P: +41(0)61-481-6611 M: email@example.com Media Inquiries: Ulrich L. Schneppel York Communications GmbH Henric Petri-Strasse 6 4051 Basel, Switzerland P: +41(0)61-508-2917 M: firstname.lastname@example.org [email@example.com ]
SOURCE Cytis AG